First CDK 4/6 Inhibitor Heads to Market

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-nb2015-028
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

To Cycle or Fight - CDK 4/6 Inhibitors at the Crossroads of Anti-Cancer Immunity

Clinical Cancer Research
Cancer ResearchOncology
2018English

Notch Targets the CDK Inhibitor Xic1 to Regulate Differentiation but Not the Cell Cycle in Neurons

EMBO Reports
BiochemistryGeneticsMolecular Biology
2006English

This Little Chemistry Went to Market First.

Chemical and Engineering News
Chemical Engineering
1988English

Multiple CDK Inhibitor Dinaciclib Suppresses Neuroblastoma Growth via Inhibiting CDK2 and CDK9 Activity

Scientific Reports
Multidisciplinary
2016English

Management of Adverse Events During Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitor-Based Treatment in Breast Cancer

Therapeutic Advances in Medical Oncology
Oncology
2018English

First Biosimilar Drug Set to Enter US Market

Nature
Multidisciplinary
2015English

Cooperating Oncogenes Converge to Regulate Cyclin/CDK Complexes.

Genes and Development
GeneticsDevelopmental Biology
1997English

Introduction to the Volume 4, First Issue

Journal of Interventional Gastroenterology
2014English

Figure 6: Details of Heads and Mouth Parts for Comparison.

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy